公开(公告)号：US20230364115A1

公开(公告)日：2023-11-16

申请号：US18029543

申请日：2021-10-01

申请人： Mydecine Innovations Group Inc.

发明人： John C Gustin ,  Michael J Mccarthy

IPC分类号： A61K31/675 ,  A61K31/4045 ,  A61K31/70 ,  A61K31/7042 ,  A61K31/192 ,  A61K31/53 ,  A61K31/19 ,  A61K31/196 ,  A61K31/427 ,  A61K31/277 ,  A61K31/015 ,  A61K31/352 ,  A61K31/437 ,  A61K31/165 ,  A61K31/4409 ,  A61K31/137 ,  A61K31/15 ,  A61K31/135 ,  A61K31/5375 ,  A61K31/421

CPC分类号： A61K31/675 ,  A61K31/4045 ,  A61K31/70 ,  A61K31/7042 ,  A61K31/192 ,  A61K31/53 ,  A61K31/19 ,  A61K31/196 ,  A61K31/427 ,  A61K31/277 ,  A61K31/015 ,  A61K31/352 ,  A61K31/437 ,  A61K31/165 ,  A61K31/4409 ,  A61K31/137 ,  A61K31/15 ,  A61K31/135 ,  A61K31/5375 ,  A61K31/421

摘要： The present invention provides compositions and methods for the treatment of a serotonin receptor related disease or condition in a subject in need thereof. A composition of the invention includes at least one psychedelic compound, which is preferably a serotonin receptor agonist, and at least one secondary agent that modulates the activity of the serotonin receptor agonist, or the physiological response to the serotonin receptor agonist in the subject.

公开(公告)号：US20230321139A1

公开(公告)日：2023-10-12

申请号：US17714465

申请日：2022-04-06

申请人： Mary Crawford ,  Jonathon Crawford

发明人： Mary Crawford ,  Jonathon Crawford

IPC分类号： A61K33/06 ,  A61K31/17 ,  A61K47/46 ,  A61K47/06 ,  A61K31/79 ,  A61K31/473 ,  A61K31/15 ,  A61K31/045 ,  A61K31/345 ,  A61K31/34 ,  A61K9/00 ,  A61P17/02

CPC分类号： A61K33/06 ,  A61K31/17 ,  A61K47/46 ,  A61K47/06 ,  A61K31/79 ,  A61K31/473 ,  A61K31/15 ,  A61K31/045 ,  A61K31/345 ,  A61K31/34 ,  A61K9/0014 ,  A61P17/02

摘要： Wound-care composition and method of use. The composition comprises: a substrate; potassium alum; and urea. The potassium alum makes up 10.27 wt. % of the composition within a tolerance of +/- 50%; and the urea makes up 0.12 wt. % of the composition within a tolerance of +/- 50%. The method comprises applying the composition to a wound on a non-human animal.

公开(公告)号：US20230270692A1

公开(公告)日：2023-08-31

申请号：US17792020

申请日：2021-01-11

申请人： Pillai Universal LLC

发明人： Baskaran PILLAI ,  Murugan Girija DINESH

IPC分类号： A61K31/12 ,  A61K31/4706 ,  A61P31/14 ,  A61P35/00 ,  A61K31/704 ,  A61K31/7068 ,  A61K31/513 ,  A61K33/243 ,  A61K31/454 ,  A61K31/4745 ,  A61K31/475 ,  A61K31/05 ,  A61K31/15 ,  C07C49/255 ,  C07C49/258 ,  C07C43/253 ,  C07C251/16

CPC分类号： A61K31/12 ,  A61K31/4706 ,  A61P31/14 ,  A61P35/00 ,  A61K31/704 ,  A61K31/7068 ,  A61K31/513 ,  A61K33/243 ,  A61K31/454 ,  A61K31/4745 ,  A61K31/475 ,  A61K31/05 ,  A61K31/15 ,  C07C49/255 ,  C07C49/258 ,  C07C43/253 ,  C07C251/16

摘要： The present disclosure provides compounds and compositions that are useful in treating chronic disorders, including cancer and viral diseases.

公开(公告)号：US20230233486A1

公开(公告)日：2023-07-27

申请号：US18193055

申请日：2023-03-30

申请人： CLEXIO BIOSCIENCES LTD.

发明人： Johanna SCHUMANN ,  Dorit MIMROD

IPC分类号： A61K31/135 ,  A61P25/24 ,  A61K31/137 ,  A61K31/138 ,  A61K31/15 ,  A61K31/343 ,  A61K31/381 ,  A61K31/4525 ,  A61K45/06

CPC分类号： A61K31/135 ,  A61P25/24 ,  A61K31/137 ,  A61K31/138 ,  A61K31/15 ,  A61K31/343 ,  A61K31/381 ,  A61K31/4525 ,  A61K45/06

摘要： The present disclosure provides methods for safe and efficacious administration of esketamine.

公开(公告)号：US20230157980A1

公开(公告)日：2023-05-25

申请号：US17275581

申请日：2019-09-11

申请人： HOUGH EAR INSTITUTE

发明人： Richard D. KOPKE

IPC分类号： A61K31/198 ,  A61K31/15 ,  A61P41/00 ,  A61P27/16

CPC分类号： A61K31/198 ,  A61K31/15 ,  A61P41/00 ,  A61P27/16

摘要： Disclosed here is a method of alleviating negative effects of cochlear implant surgery in a subject in need thereof comprising administering effective amounts of 2,4-disulfonyl α-phenyl tertiary butyl nitrone (2,4-DSPBN) or a pharmaceutically acceptable salt thereof and N-acetylcysteine (NAC) or a pharmaceutically acceptable salt thereof to a subject prior to, during, and/or after undergoing cochlear implant surgery.

公开(公告)号：US11655208B2

公开(公告)日：2023-05-23

申请号：US17548669

申请日：2021-12-13

申请人： Jiangnan University

发明人： Xiulan Sun ,  Yongli Ye ,  Qianqian Hong ,  Deping Xu ,  Yinzhi Zhang ,  Shuxiang Geng

IPC分类号： C07C249/02 ,  A61K31/15 ,  B01D11/02 ,  A61K36/52 ,  B01D15/12 ,  B01D15/42

CPC分类号： C07C249/02 ,  A61K31/15 ,  A61K36/52 ,  B01D11/0288 ,  B01D11/0292 ,  B01D15/125 ,  B01D15/426

摘要： The present disclosure discloses a 1-carboxy-2-hydroxy-3-iminopropane and an extraction method thereof, and belongs to the technical fields of food, health food and medicine. A method for extracting the 1-carboxy-2-hydroxy-3-iminopropane of the present disclosure includes the following steps: (1) adding a diaphragma juglandis fructus powder into an ethanol solution for extraction and filtration to obtain a supernatant, and conducting concentration on the supernatant under reduced pressure to obtain a walnut alcohol extract; (2) adding a filter residue of step (1) into water for extraction and filtration to obtain a supernatant, and conducting concentration on the supernatant under reduced pressure to obtain a walnut water extract; and (3) mixing the walnut alcohol extract and the water extract to obtain a diaphragma juglandis fructus mixed extract, sequentially conducting elution through an AB-8 type macroporous resin column, an MCI column and an ODS column, and conducting separation to obtain a precipitate, namely the 1-carboxy-2-hydroxy-3-iminopropane. In the present disclosure, the 1-carboxy-2-hydroxy-3-iminopropane in diaphragma juglandis fructus is found for the first time and has great sedation and hypnosis activity.

公开(公告)号：US20230134958A1

公开(公告)日：2023-05-04

申请号：US17976220

申请日：2022-10-28

申请人： Umecrine Cognition AB

发明人： Magnus Doverskog ,  Mette Lauridsen ,  Bruce Frederick Scharschmidt

IPC分类号： A61K31/568 ,  A61P1/16 ,  A61K31/15 ,  A61K31/138 ,  A61K31/4178 ,  A61K31/167 ,  A61K31/575 ,  A61K38/13 ,  A61K31/485 ,  A61K31/165 ,  A61K39/395 ,  A61K31/7016 ,  A61K31/437 ,  A61K31/341 ,  A61K31/519 ,  A61P25/00

摘要： The present invention is directed to a method for the treatment of cognitive impairment in a cirrhotic patient with hepatic encephalopathy (HE), said patient having a CRT index (continous reaction time index) below 1.9 at baseline (prior to treatment), whereby the compound golexanolone (3α-ethynyl-3β-hydroxyandrostan-17-one oxime) of formula (I) or a pharmaceutically acceptable salt thereof, is administered to said patient.

公开(公告)号：US11633377B2

公开(公告)日：2023-04-25

申请号：US17169928

申请日：2021-02-08

申请人： Vanda Pharmaceuticals Inc.

发明人： Marlene Michelle Dressman ,  Louis William Licamele ,  Mihael H. Polymeropoulos

IPC分类号： A61K31/343 ,  A61K31/00 ,  A61K45/06 ,  A61K31/15 ,  A61K31/277 ,  A61K31/496 ,  G01N30/72 ,  G16H50/20 ,  G01N33/74 ,  G01N33/68 ,  A61K9/00

摘要： Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.

公开(公告)号：US20220378769A1

公开(公告)日：2022-12-01

申请号：US17771664

申请日：2020-03-06

申请人： Algernon Pharmaceuticals Inc.

发明人： Mark Williams

IPC分类号： A61K31/445 ,  A61K31/454 ,  A61K31/506 ,  A61K31/496 ,  A61K31/4402 ,  A61K31/15 ,  A61K31/138 ,  A61K31/343 ,  A61P11/14

摘要： The use of glutamate 2b receptor antagonists and sigma receptor agonists as antitussives to treat or prevent a cough is disclosed. In preferred embodiments, the glutamate 2b receptor antagonist is ifenprodil or radiprodil. Preferred sigma receptor agonists include fluvoxamine, fluoxetine, excitalpram, and donepezil.

公开(公告)号：US11484577B2

公开(公告)日：2022-11-01

申请号：US16077949

申请日：2017-02-14

申请人： INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) ,  UNIVERSITE PAUL SABATIER TOULOUSE III ,  CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE

发明人： Philippe Valet ,  Cedric Dray ,  Vincent Minville ,  Bernard Frances ,  Francois Labaste ,  Claire Vinel

IPC分类号： A61K38/22 ,  A61K31/08 ,  A61K31/02 ,  A61K31/15 ,  A61K33/00 ,  A61P23/00 ,  A61P25/28 ,  A61K31/015

摘要： The present invention relates to methods and pharmaceutical compositions for the treatment of post-operative cognitive dysfunction. In particular, the present invention relates to a method of treating post-operative cognitive dysfunction in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an APJ receptor agonist.